➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Colorcon
Johnson and Johnson
McKinsey
Medtronic

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RABEPRAZOLE SODIUM

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Rabeprazole Sodium

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01286194 A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms Completed Eisai Inc. Phase 4 2006-04-01 This is a multi-center, open-label, all-comers OTC actual use study in pharmacy sites where the principal investigator will be a pharmacist.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Rabeprazole Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00125736 A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium Completed Eisai Limited Phase 4 2005-08-01 The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.
NCT00165646 A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease Completed Eisai Co., Ltd. Phase 3 2004-09-01 To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.
NCT00165672 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease Completed Eisai Limited Phase 3 2005-05-01 To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rabeprazole Sodium

Condition Name

Condition Name for Rabeprazole Sodium
Intervention Trials
Healthy 9
Gastroesophageal Reflux 6
Gastroesophageal Reflux Disease (GERD) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rabeprazole Sodium
Intervention Trials
Gastroesophageal Reflux 12
Ulcer 2
Esophagitis, Peptic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rabeprazole Sodium

Trials by Country

Trials by Country for Rabeprazole Sodium
Location Trials
United States 62
Japan 50
Poland 3
India 2
Australia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rabeprazole Sodium
Location Trials
California 4
Kentucky 3
North Dakota 3
Georgia 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rabeprazole Sodium

Clinical Trial Phase

Clinical Trial Phase for Rabeprazole Sodium
Clinical Trial Phase Trials
Phase 4 7
Phase 3 7
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rabeprazole Sodium
Clinical Trial Phase Trials
Completed 28
Active, not recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rabeprazole Sodium

Sponsor Name

Sponsor Name for Rabeprazole Sodium
Sponsor Trials
Eisai Inc. 8
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 6
Mylan Pharmaceuticals 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rabeprazole Sodium
Sponsor Trials
Industry 34
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Merck
McKesson
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.